On the Record · Medtronic
Medtronic acquisitions, on the record
The businesses Medtronic bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Intersect ENTWord for word“On May 13, 2022, the Company acquired Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader.” 10-K for 2024 | acquisition | On May 13, 2022 | — |
Affera, Inc.Word for word“On August 30, 2022, the Company acquired Affera, Inc. (Affera) a privately-held company focused on the development of cardiac mapping and navigation systems and catheter-based cardiac ablation technologies.” 10-K for 2024 | acquisition | On August 30, 2022 | — |
Renal Care Solutions business (half of RCS business)Word for word“Fiscal year 2023 included non-cash charges of $136 million, primarily related to impairments of goodwill and changes in the carrying value of the disposal group, as a result of the April 1, 2023 sale of half of the Company's RCS business.” 10-K for 2024 | divestiture | April 1, 2023 | — |
Ventilator product lineWord for word“On February 20, 2024, the Company announced the decision to exit its ventilator product line and retain and combine the remaining Patient Monitoring and Respiratory Interventions (PMRI) businesses into one business unit called Acute Care and Monitoring (ACM).” 10-K for 2024 | divestiture | On February 20, 2024 | — |
Mechanical Circulatory Support (HVAD System) businessWord for word“In June 2021, the Company announced the decision to stop the distribution and sale of the Medtronic HVAD System.” 10-K for 2024 | divestiture | In June 2021 | — |
Businesses acquired in fiscal year 2025 (not named)Word for word“The acquisition date fair value of net assets acquired during fiscal year 2025 was $ 128 million, consisting of $ 159 million of assets acquired and $ 31 million of liabilities assumed.” 10-K for 2025 | acquisition | during fiscal year 2025 | $ 128 million |
Businesses acquired in fiscal year 2024 (not named)Word for word“The acquisition date fair value of net assets acquired during fiscal year 2024 was $ 335 million, consisting of $ 338 million of assets acquired and $ 3 million of liabilities assumed.” 10-K for 2025 | acquisition | during fiscal year 2024 | $ 335 million |
RCS business (half sold to Mozarc)Word for word“on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50 % equity interest in Mozarc.” 10-K for 2025 | divestiture | on April 1, 2023 | — |
CathWorks Ltd.Word for word“On April 20, 2026, the Company acquired all the remaining outstanding shares of CathWorks Ltd. (CathWorks), a privately held medical device company, for $525 million of consideration transferred, including $115 million of contingent consideration.” 10-K for 2026 | acquisition | On April 20, 2026 | $525 million |
Scientia VascularWord for word“On June 12, 2026, the Company closed on the acquisition of all outstanding shares of Scientia Vascular (Scientia) (a privately held company).” 10-K for 2026 | acquisition | On June 12, 2026 | — |
SPR Therapeutics, Inc.Word for word“On May 20, 2026, the Company announced its intent to acquire all outstanding equity of SPR Therapeutics, Inc., a privately held medical technology company.” 10-K for 2026 | agreed acquisition | On May 20, 2026 | — |
| Fiscal year ended | Cash paid for acquisitions (net of cash acquired) | Cash received from selling businesses | Goodwill from acquisitions |
|---|---|---|---|
| 2017-04-28 | $1.32 billion | $0 | $732 million |
| 2018-04-27 | $137 million | $6.06 billion | $52 million |
| 2019-04-26 | $1.83 billion | $0 | $1.51 billion |
| 2020-04-24 | $488 million | $0 | $333 million |
| 2021-04-30 | $994 million | — | $816 million |
| 2022-04-29 | $91 million | — | $80 million |
| 2023-04-28 | $1.87 billion | — | $1.34 billion |
| 2024-04-26 | $211 million | — | $131 million |
| 2025-04-25 | $98 million | — | $108 million |
| 2026-04-24 | $406 million | — | $555 million |
Deal filings since 2016
- 2025-09-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-06-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-03-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-09-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2021-12-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-09-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2020-05-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-07-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-03-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2018-12-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-03-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Medtronic’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2024) and the financial data it files with the SEC, as of 2026-06-18. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.